ASH 2018: Advances in RRMM
Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.
Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.
Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.
Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.
Professor Stefan Schreiber (Germany) discusses the future of therapies in IBD.
Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.
Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients’ care.
WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.
Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said… read more.
Hot topics in lung cancer – interviews from ASCO 2018.
Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.
The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.